HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

H 74

structure given in first source

Also Known As:

(3,4-dichloroanilino)phenylacetonitrile; H-74

Networked: 12 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Nitriles: 227
  - Acetonitriles: 2
    - H 74: 12

Experts

1.	Fujita, Fumiko: 2 articles (02/2005 - 04/2002)
2.	Fujita, Masahide: 2 articles (02/2005 - 04/2002)
3.	Koike, Masako: 2 articles (02/2005 - 04/2002)
4.	Li, Ming-Yi: 1 article (08/2014)
5.	Li, Ran: 1 article (08/2014)
6.	Liu, Bin: 1 article (08/2014)
7.	Liu, Jie: 1 article (08/2014)
8.	Liu, Zhong-Kao: 1 article (08/2014)
9.	Miao, Hui-Lai: 1 article (08/2014)
10.	Qiu, Zhi-Dong: 1 article (08/2014)

Related Diseases

1.	Neoplasms (Cancer) 02/15/2005 - "MEN4901/T-0128 administered i.v. showed a marked antitumor activity in each of these tumor models, producing tumor shrinkage in the models of H-204 and H-181 carcinomas at its maximum tolerated dose of 80 mg/kg (expressed as T-2513) weekly for 4 weeks (q7d x 4) and tumor-shrinking or marked growth-inhibitory effects in the models of H-81, H-110, Mqnu-1, H-74, and H-48 carcinomas at 1/3 of its maximum tolerated dose (q7d x 4). " 11/01/1995 - "In addition, CGP 41251 decreased the number of PCNA (proliferating cell nuclear antigen) immunoreactive cells in human tumor cells H-55, H-26 and H-74. " 11/01/1994 - "We investigated anti-tumor activity combining gemcitabine with cisplatin (CDDP) or vindesine (VDS) with a lung cancer line H-74 that was relatively insensitive to gemcitabine. "
2.	Lung Neoplasms (Lung Cancer) 11/01/1994 - "We investigated anti-tumor activity combining gemcitabine with cisplatin (CDDP) or vindesine (VDS) with a lung cancer line H-74 that was relatively insensitive to gemcitabine. " 04/01/2002 - "We have investigated the antitumor activity of gemcitabine combined with cisplatin (CDDP) or vindesine (VDS) using a lung cancer line, H-74, that was insensitive to almost all antitumor drugs and relatively insensitive to gemcitabine. " 12/01/1994 - "We described the induction of resistance, cross-resistance to cisplatin (CDDP) or vindesine (VDS) and the side effects of gemcitabine, a new Ara-C derivative, in human lung cancers, Mqnu-1 or H-74 xenografted in nude mice. "
3.	Pneumonia (Pneumonitis) 01/01/2022 - "ROC analysis found the AUC, cutoff, sensitivity, and specificity results of ESR for pneumonia were 0.827, 37 mm/h, 77%, and 78%; for intensive care were 0.625, 50 mm/h, 74%, and 52; and for mortality were 0.606, 51 mm/h, 71%, and 49%, respectively. "
4.	Pain (Aches) 01/01/1993 - "There was no difference in the numbers without pain for > or = 4 h (74%, 64%, and 69% of groups I, II, and III), or those requiring analgesics by 24 h (66% overall). "
5.	Infarction (Infarctions) 11/01/1993 - "Findings with thrombolytic therapy initiated < or = 1.5 (96 patients) versus > 1.5 h (74 patients) were the following: initial extent of epicardial injury, 1.6 +/- 0.9 versus 1.4 +/- 0.7 mV, p = NS; infarct size by cardiac enzyme release 646 +/- 634 versus 886 +/- 712 IU/liter, p < 0.05; ejection fraction 57 +/- 14% versus 51 +/- 13%, p < 0.05; regional dyssynergic area 24 +/- 22 versus 33 +/- 24 U, p < 0.05; 21-day mortality 1 of 96 versus 5 of 74 patients (1% vs. 7%, p < 0.05). "

Related Drugs and Biologics

1.	Vindesine (Vindesin)
2.	Cisplatin (Platino)
3.	Gemcitabine
4.	Proliferating Cell Nuclear Antigen (PCNA)
5.	Enzymes
6.	Cytarabine (Cytosar-U)
7.	Antineoplastic Agents (Antineoplastics)
8.	Analgesics (Analgesic Drugs)
9.	T 0128
10.	midostaurin

Related Therapies and Procedures

1.	Thrombolytic Therapy
2.	Critical Care (Surgical Intensive Care)